Twenty autologous bone marrow (BM) and 25 peripheral blood stem cell (PBSC) grafts were collected from a total of 40 consecutive patients with BCR-ABL + acute lymphoblastic leukemia (ALL) in first (n = 37) or second (n = 3) complete morphological remission and subsequently purged with a cocktail of anti-CD19, -CD10, AB4 MoAbs and immunomagnetic beads (IMB). Residual BCR-ABL-positive cells before purging were detected in 19 of 20 BM grafts at a median of 4 (range 0-6) logs and in 17 of 25 evaluable PBSC grafts at a median of 1 (range 0-3) log above the limit of detection assessed by a semiquantitative limiting log 10 -dilution RT-PCR (P Ͻ 0.0001). IMB purging depleted a median of 2.5 (range 1-4) log of residual BCR-ABL + cells from BM and a median of 1 (range 0-2) log from PBSC grafts, achieving RT-PCR negativity in 1/20 BM and 12/25 PBSC grafts after purging. Cell recoveries were 62% and 86% (P Ͻ 0.0001) of MNC and 74% and 97% (P = 0.065) of CD34 + cells after BM and PBSC purging, respectively. BM purging was superior using the triple MoAb cocktail which depleted 2.64 ؎ 0.4 log (n = 14) compared to 1.6 ؎ 0.4 log (n = 5) using the MoAb cocktail not including AB4 (P = 0.02). We conclude that unpurged BM grafts contain 2-3 log more residual BCR-ABL + cells than unpurged PBSC grafts and that purging efficacy is superior in BM compared to PBSC grafts, but median titers in purged BM grafts still exceed those in purged PBSC grafts. Bone Marrow Transplantation (2000) 25, 97-104.
Conventional chemotherapy induces complete morphological remissions in 60-70% of patients, but these are rarely, if ever, durable. 5 Thus, bone marrow or stem cell transplantation is usually essential to prevent fatal relapse. Allogeneic bone marrow transplantation from an HLA-matched family donor cures about 30-40% of patients. [6] [7] [8] [9] After transplantation from matched unrelated donors (MUD) long-term disease-free survival was 49% in a series of 18 patients with a median age of 25 years. 10 However, the median age of patients with BCR-ABL-positive ALL in the German multicenter adult ALL (GMALL) 5 and other large multicenter studies is 45 years. Thus, for older patients without a matched sibling donor, autologous transplantation remains an option for cure with a disease-free survival at 3 years of 20-30%. 11 Relapse rates of 65-70% account for the majority of treatment failures after autologous transplants. The higher incidence of post-transplant relapse after autologous compared to allogeneic transplantation is likely due to the lack of a graft-versus-leukemia effect but possibly also to reinfusion of leukemic cells with the graft 12 or a combination of the two. It is difficult to distinguish lack of GVL from reinfusion of residual leukemia in contributing to post-transplant relapse. As a first approach we characterized residual leukemia in the grafts and studied the feasibility and the depletion efficiency of available purging methods. 13, 14 We previously demonstrated that marrow harvested in morphological remission from 14 patients with BCR-ABLpositive ALL was consistently contaminated with BCR-ABL-positive cells, 14 providing a rationale for subsequent in vitro purging using anti-CD10, -CD19 and AB-4 antibodies and immunomagnetic beads. Purging depleted a median of 3 log of BCR-ABL-positive cells without achieving complete PCR negativity. In contrast, leukapheresisderived peripheral blood stem cell grafts from four patients with BCR-ABL-positive ALL revealed 2 to 3 log less contamination with residual BCR-ABL-positive cells and became PCR negative after immunomagnetic bead purging. 13 The objectives of the present study were first to investigate the difference in leukemic contamination between bone marrow and peripheral blood autografts in a larger prospective series comprising 40 consecutive BCR-ABLpositive ALL patients, second to compare the efficiency of immunomagnetic bead purging of bone marrow vs periph-Bone Marrow Transplantation eral blood grafts, and third, to define factors with potential impact on purging efficiency.
Patients and methods

Patients
A total of 40 patients with BCR-ABL-positive ALL without an HLA-identical sibling donor were included in this study. They were referred to our institution for autologous bone marrow (n = 20) or peripheral blood stem cell harvests (n = 20) with subsequent IMB purging from 25 different hospitals from June 1992 to February 1998. The median age at the time of diagnosis was 40 (range 6-63) years. The patients' characteristics are detailed in Table 1 . The BCR-ABL rearrangement at diagnosis was routinely assessed in a central laboratory of the German multicenter adult ALL (GMALL) study. 15, 16 Thirty-seven of 40 patients were recruited in first CR and three patients in second CR. At the time of harvest all patients were in complete remission by cytological criteria. During the initial phase of the study between June 1992 and June 1994, only autologous BM harvests were performed (n = 14).
14 The subsequent protocol including PBSC harvest was initiated in 1994. 13 Since then, patients mobilizing sufficient numbers of CD34 + cells were leukapheresed (n = 20) while patients with unsatisfactory CD34 mobilization (Ͻ10 CD34 + cells/l PB) remained candidates for BM harvest (n = 6). Written informed consent was obtained from each patient.
Chemotherapy prior to stem cell harvest
Six of 40 patients (patients [1] [2] [3] [4] [5] 22) , diagnosed prior to 1994, received induction and consolidation therapies according to the German multicenter adult ALL (GMALL) 04/89 protocol, 4 another 32 patients were treated according to the subsequent GMALL 05/93 protocol. 5 The contents of these protocols 5 and the relevant cycles for this study 13, 14 have been described in detail elsewhere. One single infant patient received the pediatric COALL-92 protocol, 17 one patient was treated according to an Austrian adult ALL protocol. 18 Table 1 details the chemotherapy protocol, the time from diagnosis to harvest and the interval from completing the preceding cycle of chemotherapy for each individual patient.
Harvest and processing of bone marrow (BM)
Seven patients (patients 1-4, 15, 18, 19) received prestimulation with 300 g G-CSF s.c. for 5 consecutive days prior to collection of bone marrow. Bone marrow cells were harvested under general anesthesia by multiple aspirations from the posterior iliac crest on both sides. Mononuclear cells (MNC) were separated over a Ficoll density gradient using a COBE 2991 (COBE, Lakewood, CA, USA) blood cell washer. The MNC fraction was washed twice in normal saline supplemented with 2% human serum albumin and resuspended for purging procedures in 100 ml S-MEM containing 50% AB0-compatible fresh frozen plasma.
Harvest and processing of peripheral blood stem cells (PBSC)
Patients scheduled for peripheral blood stem cell harvest were mobilized with 5-10 g/kg rhG-CSF (Neupogen, Amgen, Thousand Oaks, CA, USA), procedures beginning 1-5 days after the last day of chemotherapy prior to leukapheresis. Blood counts and monitoring of CD34
+ cells were performed daily as described previously. 13 Leukaphereses were performed using a Fenwal CS 3000 plus (Baxter, Munich, Germany) with the Baxter stem cell collection program. Ten to 16 l of blood were processed at a flow rate of 50-70 ml/min. The apheresis product was collected in a volume of 50 ml.
Immunomagnetic bead purging
Dynabeads (Dynal, Hamburg, Germany) and the Baxter MaxSep Magnetic cell separator (Baxter, Deerfield, IL, USA) were used for IMB purging in all patients. From 1992 to 1996, a triple cocktail of directly coupled Dynabeads as detailed below was used in the first 15 of a total of 20 BM patients and the first five of a total of 20 PBSC patients. From 1996 directly coupled CD10-and AB4-Dynabeads were no longer available and the purging protocol had to be modified. Thus, the purging methodology was not homogeneous throughout this study. According to the available stock of beads, a double cocktail of direct CD19 and CD10 Dynabeads was used for five purging procedures in another three PBSC patients as detailed in Table 1 . Only direct CD19 beads were used in another two BM and 10 PBSC purging procedures. Another three BM and two PBSC grafts were purged indirectly using a cocktail of CD19 and CD10 MoAbs. Purging was always completed on the day of the stem cell harvest.
Direct immunomagnetic bead purging
For direct IMB purging, mouse IgM monoclonal antibodies (MoAb) were directly coupled to Dynabeads, and were supplied in 10 ml vials each containing approximately 4 × 10 9 MoAb beads (Dynal). Three different MoAbs were used: an IgM-anti-CD19 (clone AB1 19 ), an IgM-anti-CD10 20 and AB4, an anti-MHC class II IgM-MoAb. 21, 22 The purging procedure was described in detail previously.
14 Briefly, the absolute numbers of B cells in the leukapheresis product or in the MNC fraction of the bone marrow, respectively, were estimated by FACS analysis before purging. A ratio of 40 beads per target cell (=B cell) was aimed at for the first purging cycle. Incubation time was 30 min. After incubation, the bound cell/bead rosettes as well as the excess beads were removed using the Baxter MaxSep with the primary magnet being precooled to 4°C. The bead purging procedure was repeated once (second cycle).
Indirect immunomagnetic bead purging
Primary mouse IgG MoAbs and sheep anti-mouse (SAM) Dynabeads for indirect immunomagnetic bead purging were purchased at GMP quality from Baxter (Munich, Germany). Cells were first incubated for 30 min with a Bone Marrow Transplantation cocktail of 1 ml of anti-CD10 (Baxter code R9901) as well as anti-CD19 (clone HD237; Baxter code R9909) mouse IgG MoAbs as primary antibodies. After washing out unbound primary antibodies, the cell-antibody complexes were incubated with SAM Dynabeads (Baxter code R9950). The estimation of beads per target cell as well as the conditions for the purging procedure were as described above. Purged stem cells were concentrated and cryopreserved in S-MEM + 50% AB0-compatible fresh frozen plasma + 10% (final concentration) DMSO using a computer-controlled cryopreservation device (Cryoson BV-6; Cryoson, Schoellkrippen, Germany).
Flow cytometric analysis
CD34
+ cells and CD19 + cells were enumerated by flow cytometry as described in detail previously. 13 
CFU-GM assay
CFU-GM colony numbers were determined using a semisolid methylcellulose assay as described previously.
14 Briefly, MNC were plated at 0.5-1 × 10 5 MNC/ml in quadruplicate 1 ml aliquots containing 1.2% methylcellulose in IMDM, 30% FCS (HyClone, Logan, UT, USA), 5 × 10 −5 m 2-mercaptoethanol (2-ME), 10 ng/ml recombinant human GM-CSF (Behring, Marburg, Germany) 10 ng/ml recombinant human G-CSF (Amgen), and incubated at 37°C, in a fully humidified 5% CO 2 atmosphere. Colonies of more than 50 cells were enumerated after 14 days and scored as CFU-GM.
Semiquantitative RT-PCR
Limiting log 10 dilution: Mononuclear cells from unpurged as well as purged samples were washed twice in PBS, and subsequently diluted in logarithmic steps in a series of Eppendorf tubes (2 ml) each containing 1.8 × 10 7 MNC from healthy volunteer blood donors down to a 1:10 8 dilution.
14 Two BCR-ABL-positive cell lines, BV-173 (M-BCR-ABL-positive) 23 and SD-1 (m-BCR-ABL-positive) 24 were used as positive controls and for standard logarithmic dilutions.
Reverse transcriptase polymerase chain reaction (RT-PCR):
Total RNA was prepared from each tube using the acid guanidinium/phenol/chloroform method. 25 Five g RNA were subjected to random-primed reverse transcription using 200 units of Moloney murine leukemia virus reverse transcriptase (GIBCO/BRL, Grand Island, NY, USA) in 20 l 10 × PCR buffer (Perkin Elmer, Emeryville, CA, USA), and 0.4 mmol/l of each desoxyribonucleotide, primed by 1500 pmol/l random hexamers. Ubiquitous RNAses were inhibited by 1.8 U/l RNA-Guard (Pharmacia, Uppsala, Sweden). PCR was performed using a Perkin Elmer Cetus Thermal Cycler in 50 l 10 × PCR buffer containing 500 mm KCl, 100 mm Tris-HCl, and 15 mm MgCl 2 , pH 8.3, and 1 unit of Taq DNA Polymerase (Perkin Elmer) primed by 2.5 mmol/ml oligomers specific for detecting 5Ј and 3Ј sequences of the M-BCR-ABL and m-BCR-ABL-rearranged RNA transcripts. 3 Cycling conditions for PCR performance were 95°-56°-72°C for M-BCR-ABL-primers, and 95°-60°-72°C for m-BCR-ABLprimers (denaturation/annealing/extension). To further enhance the sensitivity of detection amplified DNA samples were reamplified using BCR-ABL-specific nested primers with cycling conditions as before. Simultaneous amplification of normal c-abl sequences served as a standard for the quality of transcripts amplified and to demonstrate the presence of amplifiable DNA in those samples yielding no signal specific for the BCR-ABL fusion. Amplification products were run on an ethidium bromide stained 2% agarose gel. The results were expressed as log 10 of the highest dilution with a positive RT-PCR signal. 
Estimation of total BCR-ABL + cell counts in BM and PBSC grafts
Statistical analysis
Descriptive statistics, data comparison with the two-tailed Student's t-test and linear regression analysis were performed and plotted using the GraphPad Prism software package.
Results
Yield of nucleated cells, CFU-GM and CD34 + cells in autologous BM and PBSC grafts
The yields of total nucleated cells (TNC) were a median of 16 × 10 9 (range 0.5-48 × 10 ) TNC in 20 BM harvests, respectively. Total cell numbers in the MNC fraction of BM grafts after Ficoll separation were a median of 4 × 10 9 (range 0.7-25.9 × 10 9 ). The median total numbers of CD34 + cells and CFU-GM were 1.9 × 10 7 and 1.2 × 10 7 in BM, and 3.8 × 10 8 and 4.9 × 10 7 in PBSC, respectively (Figure 1 ).
Cell recoveries after purging of BM vs PBSC grafts
After bone marrow purging, medians of 62% (range 46-97%) of MNC, 74% (range 14-128%) of CD34 + cells and 61% (range 11-106%) of CFU-GM were recovered. Median cell recoveries after PBSC purging were 86% (range 52-114%) for TNC, 97% (range 22-130%) for CD34 + cells, and 118% (range 26-193%) for CFU-GM, significantly exceeding recoveries after BM purging (P Ͻ 
Interval between chemotherapy and BM vs PBSC harvest
Autologous bone marrow was harvested in 20 patients at a median of 36 (range 19-69) days after completing the previous cycle of chemotherapy. In contrast, the intervals between completing the corresponding previous cycle of chemotherapy and PBSC leukapheresis were significantly shorter: 25 PBSC were harvested in 20 patients after a median of 18 (range 11-24) days.
Residual BCR-ABL-positive cells in unpurged BM grafts
Residual BCR-ABL-positive cells were consistently detected in all except one of 20 autologous BM grafts tested. By semiquantitative RT-PCR, the median prepurge titer in the Ficolled MNC fraction was 4 (range 2-6) log above the limit of detection. The median estimated proportions of BCR-ABL + cells were 1% of Ficolled MNC and 0.2% of unseparated TNC, respectively. Total BCR-ABL + cells in unpurged BM grafts were estimated as median 2.9 × 10 7 (range Ͻ10 3 to 2.5 × 10 9 ) (Figure 2 ).
Residual BCR-ABL-positive cells in unpurged PBSC grafts
In contrast to BM grafts, eight of 25 (32%) unpurged PBSC grafts were already BCR-ABL negative. (range Ͻ5 × 10 3 to 2 × 10 7 ) in unpurged PBSC grafts (Figure 2) . The difference between RT-PCR titers in BM and PBSC is highly significant (P Ͻ 0.0001).
Depletion of residual BCR-ABL-positive cells assessed by semiquantitative RT-PCR
Immunomagnetic bead purging depleted median 2.3 log (range 1-4 log, n = 19) of BCR-ABL-positive cells from autologous BM grafts without achieving PCR negativity in any of the purged BM grafts with detectable signal prior to purging. The median PCR titer after BM purging was 1 log (range 0-4 log) above the limit of detection. The estimated total numbers of BCR-ABL + cells in purged BM grafts were a median of 6 × 10 4 (range Ͻ1 × 10 3 to 2 × 10 7 ) (Figure 2) .
Four of 17 PBSC grafts with a detectable prepurge signal became PCR negative by purging. Including those grafts which were already PCR negative prior to purging (n = 8), a total of 12 of 25 purged PBSC grafts (48%) were PCR negative. Thirteen of purged PBSC grafts (52%) remained PCR positive at a median level of 1 log above the limit of detection. In these grafts, the factor of depletion was a median of 1 log (range 0-у2 log).
The estimated total numbers of BCR-ABL + cells in purged PBSC grafts were a median of 6 × 10 3 (range Ͻ1 × 10 3 to 7 × 10 5 ) (Figure 2 ).
Purging efficiency in bone marrow compared to PBSC grafts
The depletion achieved in BM grafts significantly exceeded the depletion achieved in PBSC grafts (median 2.3 log vs median 1 log, P Ͻ 0.001). Nevertheless, due to the median 3 log higher prepurge titers in BM, the median postpurge RT-PCR titer in purged BM grafts still exceeded the median titer in postpurge PBSC grafts (median 1 log vs median 0 log above the limit of detection, P Ͻ 0.0001).
Variables influencing efficiency of immunomagnetic bead purging
Since the purging methodology was not homogeneous throughout this study, the following parameters in BMpurging were analyzed.
Trends over time:
A linear regression of RT-PCR titers over consecutive patient numbers did not show a significant drift with time in median prepurge PCR titers (P = 0.47) (see Figure 3 ). However, depletion efficiency deteriorated from 3 to 1.5 log (P = 0.006) resulting in an increase of postpurge RT-PCR titers (P = 0.2).
MoAb cocktail: For 15 patients, bone marrow was purged with a triple MoAb cocktail including anti-CD19, -CD10 and -AB4 antibodies, whereas in a heterogenous group of five BM patients AB4 was not included. The purging efficiency in the AB4 + group was significantly superior compared to the AB4 − group (2.64 Ϯ 0.4 log vs 1.6 Ϯ 0.4 log; P = 0.02), explaining the deterioration over time.
Other variables such as total bead numbers used per purging cycle or bead numbers in relation to MNC, CD19 + target cells or incubation volume did not significantly influence postpurge PCR titers (data not shown).
Discussion
In this prospective study we compared the contamination with residual BCR-ABL-positive leukemic cells in 25 peripheral blood and 20 bone marrow-derived autologous grafts collected from a total of 40 patients with BCR-ABLpositive ALL in morphological remission. We previously found median 1.5 log lower RT-PCR titers in unmobilized peripheral blood as compared to bone marrow in nine paired samples from remission patients 26 and hypothesized that PBSC grafts might be superior to BM grafts due to a significantly lower level of residual leukemia. In another small series of four G-CSF-mobilized leukapheresis samples there was a trend for even lower RT-PCR titers. 13 These findings are substantiated to high significance by the larger series of patients presented here. The median 3 log lower RT-PCR titers in PBSC grafts were most likely not only due to the different sources of stem cells, but also to the shorter interval from previous chemotherapy to leukapheresis of a median of 18 days compared to a median of 36 days to marrow collection. Referring to a difference of about 1.5 log RT-PCR titer in paired unmobilized blood and marrow samples, 26 we estimate that earlier collection of PBSC may account for another 1.5 log. Thus we extrapolate a 1 log increase in peripheral RT-PCR titers within a 2 week period, which is in accordance with the clinical experience of early relapses seen in this disease.
A point of theoretical concern was that leukemic cells were also mobilized by G-CSF 27, 28 in a condition highly efficient in mobilizing normal CD34 + cells. No data are yet available to compare peripheral MRD in a cohort of patients not receiving G-CSF. We conclude from the consistently low RT-PCR titers in leukapheresis samples that, if at all, mobilization of total numbers of BCR-ABL-positive cells does not appear to be a major problem in the patients studied. To our knowledge, no comparable data have been published by others except those by van Rhee et al, 29 who pursued a different approach to quantitatively assess MRD in marrow and blood samples from patients with BCR-ABL-positive ALL.
While we use a limiting log-dilution RT-PCR assay in an attempt to focus on the quantitation of the number of residual BCR-ABL-positive cells, van Rhee quantitated the ratio of BCR-ABL vs ABL mRNA transcripts. He found no significant difference in BCR-ABL mRNA expression between BM and PB. Another methodological difference to our study was the interval between sampling and RNA extraction. We always extracted RNA within a maximum of 24 h after cell sampling. Van Rhee attributed negative findings in PB with a corresponding positive BM sample in a few discordant cases to poorer quality of PB specimens, a consequence in part of an interval of up to 4 days between collection of samples and processing.
In vitro purging in BCR-ABL-positive ALL reported by other investigators included either anti-CD10 MoAb and complement, 30 mafosfamide, 8, 18 combination of anti-CD10 immunotoxins and 4-HC, 31 or in two cases long-term marrow cultures. 32, 33 A total of 20 out of 55 patients autografted for BCR-ABL + ALL 8, 9, 18, [30] [31] [32] [33] [34] [35] [36] [37] [38] (not including our series 11 ) received purged marrow. 8, 18, [30] [31] [32] [33] None of these reports included monitoring of residual disease before and after purging by semiquantitative PCR.
In our study the regression analysis of prepurge RT-PCR titers in bone marrow over a 6 year period did not show a significant drift in median PCR titers. Thus, we assume that the sensitivity of our semiquantitative RT-PCR assay did not change significantly over time.
The purging efficiency in marrow grafts, however, decreased significantly by 1-1.5 log indicating an emerging methodological problem in the purging procedure. The most obvious change over time was that we had to modify our cocktail of monoclonal antibodies, since the AB4 antibody 21, 39 was only available for us until 1995. At present we assume that AB4 contributed to higher purging efficiencies since we were not able to identify any other variable with significant impact on purging efficiency.
In PBSC purging, the AB4 antibody was included in five patients. There was a trend towards a higher proportion of postpurge PCR-negative grafts in this group. However, possibly due to the small number of patients the impact on purging efficiency did not reach statistical significance.
We cannot fully explain the remarkable difference of 2.5 log in purging efficiency between BM and PBSC, but we assume that there are both methodological as well as potential biological factors.
Methodologically, this difference cannot solely be attributed to the use of the AB4 antibody. Another factor which may account for differences in purging efficiency in PBSC vs BM is the different median number of beads per incubation volume. With significantly higher median ratios of beads per target B cell for PBSC, the concentration of beads per volume, however, was a median of four times higher for BM as it was for PBSC purging.
Finally, we cannot exclude that there was a variation in the quality of the CD19 antibodies provided over the 6 year period of this study.
A possible biological explanation could be the presence of low numbers of BCR-ABL-positive leukemic progenitors with low or absent expression of the CD19 antigen 40 thus escaping the purging procedure.
Further studies to define the impact of each of these as yet hypothetical factors are ongoing. In addition, we are currently evaluating a double-purging strategy comprising a CD34 preselection followed by depletion of CD19-positive cells using the MACS (Miltenyi, Bergisch-Gladbach, Germany) cell separation device.
